Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Inclusion Criteria

• •Histologically confirmed ovarian epithelial or primary peritoneal carcinoma
• •* Recurrent or persistent after initial standard surgery or chemotherapy
• •* Incurable with standard surgery, chemotherapy, or radiotherapy
• •At least 1 unidimensionally measurable target lesion
• •* At least 20 mm by conventional techniques
• •* At least 10 mm by spiral CT scan
• •* Outside the area of prior radiotherapy
• •Accessible to guided core needle biopsy
• •Received 1 prior platinum-based chemotherapy regimen (e.g., carboplatin, cisplatin, or another organoplatinum compound) for primary disease
• •* May have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment
• •* Patients with only 1 prior platinum-based chemotherapy regimen must have an initial treatment-free interval of less than 12 months
• •* Patients with an initial treatment-free interval of more than 12 months must have progressive disease after prior platinum-based chemotherapy regimen as second-line therapy
• •No tumors involving major blood vessels
• •No evidence of CNS disease (primary brain tumor or brain metastases) within the past 5 years
• •Ineligible for higher priority Gynecologic Oncology Group (GOG) protocols (i.e., active phase III GOG protocols for the same patient population)
• •Performance status - GOG 0-2 (patients who have received 1 prior regimen)
• •Performance status - GOG 0-1 (patients who have received 2 prior regimens)
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •No known bleeding disorder or coagulopathy
• •No active bleeding
• •Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• •serum glutamate oxaloacetate transaminase (SGOT) ≤ 2.5 times ULN
• •Alkaline phosphatase ≤ 2.5 times ULN
• •PT (INR) ≤ 1.5 (INR 2-3 if on stable dose of therapeutic warfarin or low molecular weight heparin)
• •Partial thromboplastin time (PTT) \< 1.2 times control
• •Creatinine ≤ 1.5 times ULN
• •Creatinine clearance \> 60 mL/min
• •No proteinuria, as indicated by 1 of the following:
• •* Negative urine dipstick
• •* Urine protein \< 30 mg/dL
• •* Urine protein \< 1,000 mg on 24-hour urine collection
• •No clinically significant cardiovascular disease, including any of the following:
• •* Uncontrolled hypertension
• •* Myocardial infarction within the past 6 months
• •* Unstable angina within the past 6 months
• •* New York Heart Association class II-IV congestive heart failure
• •* Serious cardiac arrhythmia requiring medication
• •* Peripheral vascular disease ≥ grade 2
• •No stroke within the past 5 years
• •No pathologic condition that carries a high risk of bleeding
• •No significant traumatic injury within the past 28 days
• •No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• •No uncontrolled seizures within the past 5 years
• •No neuropathy (motor and sensory) ≥ grade 2
• •No serious non-healing wound, ulcer, or bone fracture
• •No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
• •No active infection requiring parenteral antibiotics
• •No known claustrophobia that would preclude MRI tolerance
• •No ferromagnetic implants or pacers
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for at least 3 months after study treatment
• •At least 3 weeks since prior immunologic therapy directed at malignancy
• •No prior bevacizumab
• •No other concurrent immunotherapy directed at malignancy
• •One additional prior cytotoxic regimen for recurrent or persistent disease allowed
• •No prior non-cytotoxic chemotherapy for recurrent or persistent disease
• •No concurrent chemotherapy directed at malignancy
• •At least 1 week since prior hormonal therapy directed at malignancy
• •No concurrent hormonal therapy directed at malignancy
• •Concurrent hormone replacement therapy allowed
• •Recovered from prior radiotherapy
• •No concurrent radiotherapy directed at malignancy
• •At least 28 days since prior major surgery or open biopsy and recovered
• •At least 7 days since prior core biopsy or placement of vascular access device
• •No anticipated need for major surgical procedure during study participation
• •At least 3 weeks since other prior therapy directed at malignancy
• •No prior anticancer therapy that would preclude study entry